APC/Cyanine7 anti-mouse I-A/I-E Antibody

Pricing & Availability
Clone
M5/114.15.2 (See other available formats)
Regulatory Status
RUO
Other Names
MHC class II
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
M5-114-15-2_APCCyanine7_IA-IE_Antibody_020119
C57BL/6 mouse splenocytes were stained with anti-mouse CD11b FITC and I-A/I-E (clone M5/114.15.2) APC/Cyanine7 (left) or Rat IgG2b, κ APC/Cyanine7 isotype control (right).
  • M5-114-15-2_APCCyanine7_IA-IE_Antibody_020119
    C57BL/6 mouse splenocytes were stained with anti-mouse CD11b FITC and I-A/I-E (clone M5/114.15.2) APC/Cyanine7 (left) or Rat IgG2b, κ APC/Cyanine7 isotype control (right).
Compare all formats See APC/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
107627 25 µg 76€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
107628 100 µg 234€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

These class II molecules are expressed on antigen presenting cells (including B cells) and a subset of T cells from H-2b,d,q,r bearing mice and are involved in antigen presentation to T cells expressing CD3/TCR and CD4 proteins.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Activated C57BL/6 mouse spleen cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

The M5/114.15.2 antibody reacts with a polymorphic determinant shared by the I-Ab, I-Ad, I-Aq, I-Ed, and I-Ek MHC class II alloantigens from mice carrying H-2p,r,q,b,d,u haplotypes. Clone M5/114.15.2 however does not react wtih I-Af, I-Ak, or I-As MHC class II alloantigens.1

Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemistry of frozen sections2,3,6, in vitro and in vivo blocking of antigen presentation or ligand binding4-7, and spatial biology (IBEX)17,18. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 107655 & 107656).

Application References
  1. Bhattacharya A, et al. 1981. J. Immunol. 127:2488. (IP)
  2. Viville S, et al. 1993. Cell 72:635. (IHC)
  3. Nelson AJ, et al. 1993. J. Immunol. 151:2453. (IHC)
  4. Shi Y, et al. 1998. J. Exp. Med. 187:367. (Block)
  5. Yamashita I, et al. 1993. Int. Immunol. 5:1139.
  6. Guo M, et al. 1995. Zygote 3:65. (IHC)
  7. Kim A, et al. 2004. Exp. Mol. Med. 36:428. (Block)
  8. Luckashenak NA, et al. 2006. J. Immunol. 177:5177.
  9. Venanzi ES, et al. 2007. J. Immunol. 179:5693.
  10. Christensen SR, et al. 2006. Immunity 25:417. PubMed
  11. Matte-Martone C, et al. 2008. Blood 111:3884. PubMed
  12. De Pascalis R, et al. 2008. Infect. Immun. 76:4311. PubMed
  13. Kuns RD, et al. 2009. Blood 113:5999. PubMed
  14. Sabatino JJ, et al. 2011. J. Exp. Med. 208:81. PubMed
  15. Draber P, et al. 2011. Mol Cell Biol. 22:4550. PubMed
  16. Fu H, et al. 2014. Nat Commun. 5:3436. PubMed
  17. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  18. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Xin B, et al. 2022. Hepatology. 76:630. PubMed
  2. Atalis A, et al. 2022. J Control Release. 347:476. PubMed
  3. Ge W, et al. 2022. Evid Based Complement Alternat Med. 2022:6132289. PubMed
  4. Wang R, et al. 2023. Nat Biomed Eng. 7:38. PubMed
  5. Draijer C, et al. 2023. Front Immunol. 13:1056477. PubMed
  6. Al-Saafeen BH, et al. 2023. Front Immunol. 13:1017780. PubMed
  7. Ajay AK, et al. 2022. Cell Rep. 38:110473. PubMed
  8. Wong Fok Lung T, et al. 2022. Cell Metab. 34:761. PubMed
  9. Garber C, et al. 2019. Nat Neurosci. 1.802777778. PubMed
  10. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
  11. Wilson NG, et al. 2023. iScience. 26:105991. PubMed
  12. Tang C, et al. 2023. Nat Commun. 14:1493. PubMed
  13. Rødahl I, et al. 2021. STAR Protoc. 2:100842. PubMed
  14. Wong Fok Lung T, et al. 2020. Nat Microbiol. 141:5. PubMed
  15. Engel O, et al. 2015. Stroke. 46: 3232 - 3240. PubMed
  16. Lauterbach MA, et al. 2020. Immunity. 51(6):997-1011.e7.. PubMed
  17. Li Y, et al. 2021. Basic Res Cardiol. 116:30. PubMed
  18. Shmuel-Galia L, et al. 2021. Immunity. 54(6):1137-1153.e8. PubMed
  19. Lancaster JN, et al. 2019. Nat Commun. 10:2220. PubMed
  20. Chen WS, et al. 2021. Cell Rep. 37:109974. PubMed
  21. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  22. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
  23. Molina-Sanchez P, et al. 2020. Gastroenterology. 2203:159. PubMed
  24. Li K, et al. 2022. J Immunother Cancer. 10:. PubMed
  25. Super M, et al. 2021. Nat Biomed Eng. Online ahead of print. PubMed
  26. Zhao Y, et al. 2021. Int Immunopharmacol. 93:107406. PubMed
  27. Hore ZL, et al. 2021. Wellcome Open Res. 6:68. PubMed
  28. Peres-Emidio EC, et al. 2022. Front Cell Infect Microbiol. 12:811474. PubMed
  29. Salei N, et al. 2020. J Am Soc Nephrol. 31:257. PubMed
  30. Hilpert C, et al. 2016. J Immunol. 197: 2780 - 2786. PubMed
  31. Liang Z, et al. 2020. Pain. 161:2089. PubMed
  32. An J,et al. 2017. Sci Rep.. 10.1038/s41598-017-13629-0. PubMed
  33. Chun E, et al. 2020. Immunity. 51(5):871-884.e6.. PubMed
  34. Bellelli R et al. 2018. Molecular cell. 70(4):707-721 . PubMed
  35. Riquelme SA, et al. 2020. Cell Metabolism. 31(6):1091-1106.e6. PubMed
  36. Neupane AS, et al. 2020. Cell. 183(1):110-125.e11. PubMed
  37. DeVito NC, et al. 2021. Cell Reports. 35(5):109071. PubMed
  38. Yong L, et al. 2022. Nat Commun. 13:4255. PubMed
  39. Bauer T, et al. 2021. Life (Basel). 11:. PubMed
  40. Kim S, et al. 2022. Redox Biol. 54:102347. PubMed
  41. Garland KM, et al. 2021. Front Immunol. 12:753472. PubMed
  42. Jia Q, et al. 2021. Theranostics. 4699:11. PubMed
  43. Xu Z, et al. 2020. Cancer Immunol Res. 1354:8. PubMed
  44. Céspedes P, et al. 2014. Proc Natl Acad Sci U S A. 111:3214. PubMed
  45. Acker KP, et al. 2019. iScience. 19:281. PubMed
  46. França TT, et al. 2021. JCI Insight. 6:. PubMed
  47. Guldner IH, et al. 2020. Cell. 183(5):1234-1248.e25. PubMed
  48. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  49. Covarrubias AJ, et al. 2020. Nat Metab. 1265:2. PubMed
  50. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
  51. Lim S, et al. 2016. PLoS One. 11: 0155689. PubMed
  52. Choi EW, et al. 2020. Sci Rep. 10:12001. PubMed
  53. Liu C et al. 2019. Immunity. 51(2):381-397 . PubMed
  54. Yang B, et al. 2021. Cell Biosci. 11:28. PubMed
  55. Han Y, et al. 2022. Int J Biol Sci. 18:5653. PubMed
  56. Terrazas M 2014. Int J Parasit. 44 613 . PubMed
  57. Chandra J, et al. 2016. Immunol Cell Biol. 10.1038/icb.2016.83. PubMed
  58. Ahn D, et al. 2021. Cell Reports. 35(9):109196. PubMed
  59. Bhattacharya A, et al. 2018. Neuropsychopharmacology. 43:2586. PubMed
  60. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
  61. Pizzurro GA, et al. 2021. Cancers (Basel). 13:. PubMed
  62. Hofmann J, et al. 2021. Front Immunol. 11:599495. PubMed
  63. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  64. Lowe PP, et al. 2020. J Neuroinflammation. 0.913888889. PubMed
  65. Sung PS, et al. 2022. JCI Insight. :. PubMed
  66. Wong NR, et al. 2021. Immunity. 54:2072. PubMed
  67. Bellomo A, et al. 2020. Immunity. 53(1):127-142.e7. PubMed
  68. Maniati E, et al. 2020. Cell Rep. 30:525. PubMed
  69. Mello AM, et al. 2022. Oncogenesis. 11:56. PubMed
  70. Willemsen J, et al. 2021. Cell Rep. 37:109977. PubMed
  71. Ghazal R, et al. 2016. Neoplasia. 18: 294-306. PubMed
  72. Baumann D, et al. 2020. Nat Commun. 1.969444444. PubMed
  73. Li J, et al. 2019. iScience. 16:468. PubMed
  74. Schnoegl D, et al. 2022. Front Immunol. 13:909270. PubMed
  75. Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed
  76. Kitaura F, et al. 2019. PLoS One. 14:e0220199. PubMed
  77. Hayashida E, et al. 2019. J Neuroinflammation. 0.789583333. PubMed
  78. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  79. Seenappa LM, et al. 2022. NPJ Vaccines. 7:128. PubMed
  80. Rosen SF, et al. 2022. Genome Med. 14:108. PubMed
  81. Sheng D, et al. 2022. J Immunother Cancer. 10:. PubMed
  82. Siolas D, et al. 2021. Cell Reports. 36:109578. PubMed
  83. Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed
  84. Moreno M et al. 2014. The Journal of Neuroscience. 34(24):8175-85 . PubMed
  85. Jin J, et al. 2020. Cell Reports. 30(12):4124-4136. PubMed
  86. Lavoie S, et al. 2020. Gastroenterology. 158:1359. PubMed
  87. Gundra UM, et al. 2017. Nat Immunol. 1.195833333. PubMed
  88. Hsu HP, et al. 2021. J Biol Chem. 296:100419. PubMed
  89. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  90. Schwartz C, et al. 2014. Proc Natl Acad Sci U S A. 111:5169. PubMed
  91. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  92. Smith HJ, et al. 2018. Cancer. 124:4657. PubMed
  93. Boguslawski KM, et al. 2020. Sci Adv. 6:eaax7515. PubMed
  94. Wang L, et al. 2020. J Nanobiotechnology. 18:38. PubMed
  95. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  96. Deets KA, et al. 2021. Elife. 10:. PubMed
  97. Matei DE, et al. 2021. Med (N Y). 2:864. PubMed
  98. Dai B, et al. 2021. Cell Reports Medicine. 2(8):100381. PubMed
  99. Zysset D, et al. 2016. Nat Commun. 7:13151. PubMed
  100. Castillo V, et al. 2015. PLoS One. 10: 0136620. PubMed
  101. Henningsson L, et al. 2010. Infect Immun. 78:3785. PubMed
  102. Deniset JF et al. 2019. Immunity. 51(1):131-140 . PubMed
RRID
AB_2069377 (BioLegend Cat. No. 107627)
AB_2069377 (BioLegend Cat. No. 107628)

Antigen Details

Structure
MHC class II
Distribution

B cell and activated T cells, APCs of the H-2b,d,q,r bearing mice

Function
Antigen presentation
Ligand/Receptor
CD3/TCR, CD4
Cell Type
Antigen-presenting cells, B cells, Dendritic cells, T cells, Tregs
Biology Area
Immunology, Innate Immunity
Molecular Family
MHC Antigens
Antigen References

1. Watts C. 1997. Ann. Rev. Immunol. 15:821.
2. Pamer E, et al. 1998. Ann. Rev. Immunol. 16:323.

Gene ID
14961 View all products for this Gene ID 14969 View all products for this Gene ID
UniProt
View information about I-A/I-E on UniProt.org

Other Formats

View All I-A/I-E Reagents Request Custom Conjugation
Description Clone Applications
Biotin anti-mouse I-A/I-E M5/114.15.2 FC
FITC anti-mouse I-A/I-E M5/114.15.2 FC
PE anti-mouse I-A/I-E M5/114.15.2 FC
Purified anti-mouse I-A/I-E M5/114.15.2 FC,IHC-F,IP,Block
PE/Cyanine5 anti-mouse I-A/I-E M5/114.15.2 FC
APC anti-mouse I-A/I-E M5/114.15.2 FC
Alexa Fluor® 488 anti-mouse I-A/I-E M5/114.15.2 FC,3D IHC
Alexa Fluor® 647 anti-mouse I-A/I-E M5/114.15.2 FC
Pacific Blue™ anti-mouse I-A/I-E M5/114.15.2 FC
Alexa Fluor® 700 anti-mouse I-A/I-E M5/114.15.2 FC,SB
PerCP/Cyanine5.5 anti-mouse I-A/I-E M5/114.15.2 FC
PerCP anti-mouse I-A/I-E M5/114.15.2 FC
APC/Cyanine7 anti-mouse I-A/I-E M5/114.15.2 FC
PE/Cyanine7 anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 421™ anti-mouse I-A/I-E M5/114.15.2 FC,IHC-F,SB
Brilliant Violet 510™ anti-mouse I-A/I-E M5/114.15.2 FC
Purified anti-mouse I-A/I-E (Maxpar® Ready) M5/114.15.2 FC,CyTOF®
Brilliant Violet 605™ anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 650™ anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 711™ anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 785™ anti-mouse I-A/I-E M5/114.15.2 FC
PE/Dazzle™ 594 anti-mouse I-A/I-E M5/114.15.2 FC
Alexa Fluor® 594 anti-mouse I-A/I-E M5/114.15.2 IHC-F,3D IHC
APC/Fire™ 750 anti-mouse I-A/I-E M5/114.15.2 FC
TotalSeq™-A0117 anti-mouse I-A/I-E M5/114.15.2 PG
Ultra-LEAF™ Purified anti-mouse I-A/I-E M5/114.15.2 FC,IHC-F,IP,Block
TotalSeq™-B0117 anti-mouse I-A/I-E M5/114.15.2 PG
TotalSeq™-C0117 anti-mouse I-A/I-E M5/114.15.2 PG
Spark Blue™ 550 anti-mouse I-A/I-E M5/114.15.2 FC
PE/Fire™ 640 anti-mouse I-A/I-E M5/114.15.2 FC
Spark YG™ 581 anti-mouse I-A/I-E M5/114.15.2 FC
PE/Fire™ 810 anti-mouse I-A/I-E M5/114.15.2 FC
Spark UV™ 387 anti-mouse I-A/I-E M5/114.15.2 FC
Spark Violet™ 538 anti-mouse I-A/I-E M5/114.15.2 FC
PerCP/Fire™ 806 anti-mouse I-A/I-E M5/114.15.2 FC
Spark Red™ 718 anti-mouse I-A/I-E M5/114.15.2 FC
APC/Fire™ 810 anti-mouse I-A/I-E M5/114.15.2 FC
Spark PLUS UV395™ anti-mouse I-A/I-E M5/114.15.2 FC
Go To Top Version: 5    Revision Date: 02.01.2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account